Advanced Search:
Equity Index

SAN.PA - SANOFI

€90.96  -0.8 (-0.87%)

Updated: 12:02 May 5, 2024 EST

Next Session's AI Forecast

97.71%

Avg. Accuracy (AI)

€93.12

Next Week's AI Forecast

100%

Trend's Accuracy (AI)

€92.67

SANOFI's Position Within the Drug Manufacturers - General Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

SANOFI - HISTORICAL DATA 6M

  • Last price

    €90.96

  • Daily change

    €-0.8

  • Previous Close

    €91.76

  • Last Updated

    12:02 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.32 0.33 0.12 0.06 -0.04

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.81 1.18 0.83 0.8 0.96

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
100% 100% 100% 100%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
91.99 1.12% 90.97 2.02% 89.17 0.31% 88.89

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
2.06 43.18 2.48 67.32

SANOFI Technical Analysis News

SANOFI

46, avenue de la Grande Armée,
Paris 75017
France
33 1 53 77 40 00
https://www.sanofi.com

Sectors: Healthcare
Industry: Drug Manufacturers - General
F. Time Employees: 86088
Description

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Corporate Governance

Sanofi’s ISS Governance QualityScore as of May 1, 2024 is 2. The pillar scores are Audit: 4; Board: 2; Shareholder Rights: 5; Compensation: 2.

SANOFI'S HOLDERS RANK

List of holders with stock participation in SANOFI.

Holder Rank Holder Shares Date Reported % Out Value